# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix anal...
RBC Bearings reported Q4 results with net sales up 4.9%, gross margin and EBITDA margin expanding. Backlog at $726.1M. Adjusted...